

qS-Ne2Mo Score – A New Risk Stratification Tool For Early Detection of Septic Shock in The Field of Emergency Medicine

Peter Erdelyi

University of Szeged Albert Szent-Gyorgyi Health Centre: Szegedi Tudományegyetem Szent-Gyorgyi Albert Klinikai Központ

Laszlo Papp (✉ papp.laszlo@med.u-szeged.hu)

University of Szeged <https://orcid.org/0000-0001-7038-5215>

Imre Foldesi

University of Szeged Albert Szent-Gyorgyi Health Centre: Szegedi Tudományegyetem Szent-Gyorgyi Albert Klinikai Központ

Katalin Farkas

University of Szeged Albert Szent-Gyorgyi Health Centre: Szegedi Tudományegyetem Szent-Gyorgyi Albert Klinikai Központ

Zsolt Molnar

University of Pécs Clinical Center: Pecs Tudományegyetem Klinikai Központ

Zoltan Peto

University of Szeged Albert Szent-Gyorgyi Health Centre: Szegedi Tudományegyetem Szent-Gyorgyi Albert Klinikai Központ

Research

Keywords: sepsis, septic shock, biomarkers, emergency medical services

Posted Date: August 31st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-823226/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Title Page**

2 *qS-Ne2Mo score – a new risk stratification tool for early detection of septic shock in the field*
3 *of emergency medicine*

4 Peter Erdelyi, MD (first author), University of Szeged, Department of Emergency, 6725,
5 Szeged, Semmelweis str. 6, Hungary mail: erdelyi.peter@med.u-szeged.hu

6 Laszlo Papp, PhD, University of Szeged, Department of Emergency, 6725, Szeged,
7 Semmelweis str. 6, Hungary mail: papp.laszlo@med.u-szeged.hu

8 Imre Foldesi, PharmD, PhD, University of Szeged, Institute of Laboratory Medicine, 6725,
9 Szeged, Semmelweis str. 6, Hungary mail: foldesi.imre@med.u-szeged.hu

10 Katalin Farkas, University of Szeged, Institute of Laboratory Medicine, 6725, Szeged,
11 Semmelweis str. 6, Hungary mail: lokine.farkas.katalin@med.u-szeged.hu

12 Zsolt Molnar, MD, PhD, DEEA, University of Pécs, Institute for Translational Medicine, 7624
13 Pécs, Szigeti str. 12. mail: zsoltmolna@gmail.com

14 Zoltan Peto, MD, PhD, University of Szeged, Department of Emergency, 6725, Szeged,
15 Semmelweis str. 6, Hungary mail: peto.zoltan@med.u-szeged.hu

16 correspondence to: Laszlo Papp, PhD, papp.laszlo@med.u-szeged.hu, +36/30/433-0302

17 University of Szeged, Department of Emergency, 6725, Szeged, Semmelweis str. 6, Hungary

18

19

20

21

22

23

24 Abstract

25

26 Background

27 Sepsis is one of the most significant healthcare concerns of the 21st century. In the United States
28 sepsis affect 1.7 million adults, with 270,000 fatal cases, according to the estimation of Centers
29 for Disease Control and Prevention. The management of sepsis relies on early recognition,
30 therefore the emergency departments have distinctive role in sepsis care, hence the need for
31 early reliable risk stratification tools.

32 Methods

33 A retrospective, quantitative study was performed in Department of Emergency, University of
34 Szedged. Hungary. Patients with suspected infection were enrolled to four subgroups based on
35 the results of patient examination and laboratory results. In all cases (N=276), cell population
36 data markers were analyzed along with ordinary infection biomarkers, such as CRP, PCT and
37 WBC. Performance of cell population data parameters were investigated with ROC (Receiver
38 Operating Curve) analysis.

39 Results

40 Almost all cell population biomarkers showed significant differences in the subgroup analysis.
41 Remarkable performance was found in three markers (NE-SFL/M, MO-X/M and NE-WY/M)
42 in patients having septic shock. Combining quick SOFA with these biomarkers (qS-Ne2Mo
43 score) resulted in excellent diagnostic ability for septic shock (AUC 0.914, $p < 0.001$), with good
44 sensitivity (73.9%) and excellent specificity (89 %).

45 Conclusions

46 Since determination of cell population data requires complete blood count analysis, turn-around
47 time of this novel indicator is significantly lower than other methods. qS-Ne2Mo score might
48 be used as an initial screening tool to select only those patients that need more extensive
49 laboratory investigations for their proper treatment and spare inadequate, time and money
50 consuming laboratory requests.

51 Trial Registration: University of Szedged, Ethical Committee ref. nr. 25/2016-SZTE

52 Keywords: sepsis, septic shock, biomarkers, emergency medical services

53

54

55 *qS-Ne2Mo score – a new risk stratification tool for early detection of septic shock in the field*
56 *of emergency medicine*

57 Introduction

58 Sepsis is one of the most significant healthcare concerns of the 21st century. In the United States
59 sepsis affect 1.7 million adults, with 270,000 fatal cases, according to the estimation of Centers
60 for Disease Control and Prevention [4]. The management of sepsis relies on early recognition,
61 therefore the emergency departments have distinctive role in sepsis care, hence the need for
62 early reliable risk stratification tools.

63 According to The Third International Consensus Definitions for Sepsis and Septic Shock
64 (Sepsis-3) infectious diseases can rapidly progress to life-threatening conditions such as sepsis
65 and septic shock. Therefore, an early and reliable screening tool could potentially improve
66 outcomes [16]. In suspected cases the ‘one-hour bundle’ is recommended [7]. The bundle
67 consists of fluid-, and vasopressor therapy, serum lactate measurements, microbiologic
68 sampling, and commencement of broad spectrum antibiotics. Time zero is defined as the time
69 of the triage, after which treatment should be started immediately if sepsis or septic shock is
70 suspected in order to enable the emergency team to complete all tasks of the bundle within this
71 relatively short time frame.

72 According to Sepsis-3, sepsis is defined as life-threatening organ dysfunction caused by a
73 dysregulated host response to infection. In patients with suspected infection, quick Sequential
74 Organ Failure Assessment score (qSOFA score) is recommended as an initial screening tool for
75 sepsis. This is a simple bedside risk stratification method assessing the mental status, respiratory
76 rate, and systolic blood pressure. In cases having qSOFA score two or three points, sepsis or
77 septic shock is suspected, and the one-hour bundle is to be completed. If qSOFA score indicates
78 low risk, then the recommendation is to use clinical judgement. In cases with positive qSOFA

79 score or in cases where sepsis is suspected clinically, the Sequential Organ Failure Assessment
80 score (SOFA score) is to be calculated. SOFA is a 0–24-point scale, and sepsis-related organ
81 failure is confirmed by an increase of two or more points. Septic shock is confirmed if
82 vasopressor therapy is needed to maintain mean arterial pressure over 65 mmHg and the serum
83 lactate level is above 2 mmol/l [4]. Cases having SOFA less than two points, have significantly
84 lower chance for poor outcome, we considered them as infection without organ failure.
85 Although, Sepsis-3 definitions are clear but to complete them is time-consuming and there are
86 several concerns specially with the very early phase of screening for suspected sepsis. qSOFA
87 score is neither specific nor sensitive for the poor outcome [8,11]. Using clinical judgement
88 (without any solid recommendation) brings too much subjectivity into the clinical practice. On
89 one hand, if clinical suspicion is used overzealously, then milder cases go through extensive
90 laboratory testing, additional painful blood works (ABG) and hasty administration of wide
91 spectrum antibiotics with all the adverse consequences without any real benefit. On the other
92 hand, if clinical sepsis awareness is low, consequences can be disastrous. This necessitates to
93 find objective biomarkers, which have a good additional value to the clinical parameters
94 provided by qSOFA score and reinforce the clinical decision making in this crucial, initial phase
95 of sepsis management.

96 For an emergency physician the earliest laboratory result to get is the complete blood count
97 (CBC) including white blood cell (WBC) count. Although WBC count is cheap, widely
98 available, fast, and requested in almost all cases with suspected infection, in itself not reliable
99 to detect sepsis [5]. With novel methods, analyzers can provide quantitative measurements of
100 morphological and functional features in neutrophil leukocytes, lymphocytes, and monocytes
101 with practically the same turn-around-time as WBC count. Sysmex XN analyzers use optical
102 measurements of light scattering and fluorescence to quantify different cellular characteristics

103 (i.e., internal complexity, nucleic acid content and cell size). These descriptive data are known
104 as cell population data (CPD).

105 Although CPD provides huge amount of data on white blood cells, clinical applicability in the
106 emergency setting is yet to be determined. Therefore, the aim of this retrospective study was to
107 analyze the performance of CPD parameters in the diagnosis of sepsis. We also tried to find
108 CPD parameters that could be combined with qSOFA for risk stratification benchmarked
109 against the calculated SOFA score, and the final Sepsis-3 category.

110 **Materials and methods**

111 This retrospective study was conducted at the Emergency Department (ED) of the University
112 of Szeged, Hungary. All data were collected from September 2019 until January 2020 from
113 patients who received emergency care in the ED because of a suspected infection.

114 Patient data were obtained from the hospital's electronic medical record system, based on the
115 approval of the University Ethical Committee (ref nr. 25/2016-SZTE). Basic descriptive data
116 (such as age, gender, date of service) were collected, along with data from the first medical
117 examination (blood pressure, heart rate, respiratory rate, and level of consciousness). Detailed
118 laboratory results were collected based on the initial laboratory tests, such as organ function
119 tests, coagulation tests, and CBC. Appropriate specimen were taken from all patients for
120 microbiology assessment.

121 Four subgroups were created: No-infection, Infection, Sepsis, Septic shock. For the presence of
122 infection the following criteria had to be fulfilled: a) confirmed infection either by microbiology
123 or imaging techniques such as chest X-ray / CT scan; b) SOFA score less than 2 points. As a
124 confirmation method for infection criteria (a), all analyses were performed both in the whole
125 cohort (as described in the criteria) and in the microbiology-positive subgroup ("final sample").
126 Sepsis and septic shock were diagnosed according to the Sepsis-3 definitions [4].

127 *Determination of White blood cell count, Immature granulocyte ratio and Cell population data*

128 The blood samples were collected in 3 ml Vacutainer Plastic K₃EDTA tubes (Ref.# 368857,
129 Becton-Dickinson, Franklin Lakes, NJ, USA) and were analysed using automated haematology
130 analyser Sysmex XN20 (Sysmex Corporation, Kobe, Japan) within 2 hours of sample
131 collection. The measured parameters included total blood count and cell population data (CPD)
132 of neutrophils, lymphocytes and monocytes on white blood cell differential (WDF) channel.
133 The precision of white blood cell (WBC) count determination was 3% or less according the
134 manufacturer, when the WBC count was 4.00 G/L or more. The precision of immature
135 granulocyte ratio (IGR) was 2% at the WBC count of 4.00 G/L or more.

136 WDF channel of the Sysmex XN20 haematology analysers uses optical side scatter along X
137 axis to assess the granularity and internal structure (complexity) of the cells. Fluorescence
138 intensity, which corresponds to RNA/DNA cell content, is plotted on the y-axis and is an
139 indicator for increased RNA activity. The forward scatter along the Z axis was in accordance
140 with the cell size. The parameters on X axis include neutrophils cell complexity (NE-SSC),
141 lymphocytes cell complexity (LY-X), monocytes cells complexity (MO-X), neutrophils
142 complexity and width of dispersion (NE-WX), lymphocytes complexity and width of dispersion
143 (LY-WX) and monocytes complexity and width of dispersion (MO-WX). The parameters
144 reported on the Y-axis include neutrophils fluorescence intensity (NE-SFL), lymphocytes
145 fluorescence intensity (LY-Y), monocytes fluorescence intensity (MO-Y), neutrophils
146 fluorescence intensity and the width of dispersion (NE-WY), lymphocytes fluorescence
147 intensity and the width of dispersion (LY-WY) and monocyte fluorescent intensity and width
148 of dispersion (MO-WY). The following parameters were reported on the Z-axis, neutrophils
149 cell size (NE-FSC), lymphocytes cell size (LY-Z), monocytes cell size (MO-Z), neutrophils
150 cell size and the width of dispersion (NE-WZ), lymphocytes cell size and the width of
151 dispersion (LY-WZ) and monocytes cell size and the width of dispersion (MO-WZ). The

152 precision of measured and calculated data as stated by the manufacturer are presented in Table

153 1.

	mean	CV%	mean	CV%	mean	CV%
WBC# (G/L)	32.5	1.19	4.8	1.38	1.5	4.72
NEU# (G/L)	29.6	1.13	2.8	1.85	0.77	6.39
[NE-SSC(ch)]	152.7	0.23	153.3	0.50	1.4	0.83
[NE-SFL(ch)]	42.5	0.74	48.9	1.10	1.1	1.97
[NE-FSC(ch)]	83.2	1.55	95.0	0.98	1.4	1.47
[NE-WX]	318.6	1.76	308.0	3.96	23.8	8.05
[NE-WY]	827.0	1.65	644.6	5.85	110.9	14.85
[NE-WZ]	709.7	1.77	650.1	4.14	54.9	8.23
LY# (G/L)	1.06	4.18	1.2	3.14	0.49	5.86
[LY-X(ch)]	81.5	0.76	85.7	0.57	0.5	0.57
[LY-Y(ch)]	53.6	1.12	74.8	1.64	1.5	2.37
[LY-Z(ch)]	56.5	1.40	60.5	1.30	0.8	1.24
[LY-WX]	452.0	5.46	421.9	6.82	47.8	10.71
[LY-WY]	1036.0	6.98	912.5	5.85	81.5	6.74
[LY-WZ]	646.5	6.14	541.2	3.02	36.3	6.17
MO# (G/L)	1.75	3.44	0.6	5.13	0.16	12.73
[MO-X(ch)]	121.2	0.68	119.4	0.95	2.3	1.86
[MO-Y(ch)]	95.9	1.69	108.3	4.34	12.4	10.43
[MO-Z(ch)]	65.4	1.78	69.9	2.75	2.9	4.08
[MO-WX]	263.4	6.39	252.1	10.05	33.2	12.01
[MO-WY]	865.4	5.69	731.1	7.12	143.0	31.52
[MO-WZ]	661.0	4.06	607.2	6.55	67.4	10.55

154

155 *Table 1.* Within-run imprecision of cell counts and cell population data (CPD). The mean
156 values and %CVs were obtained from 20 replicates of three patients at different concentrations
157 of white blood cells (WBC). NEU: Neutrophil granulocytes; LY: Lymphocytes; MO:
158 Monocytes

159 *Determination of C-Reactive Protein and Procalcitonin*

160 The blood samples were collected in 5 ml vacutainer tubes (Plastic STT II Advance tubes;
161 Ref.#367955, Becton-Dickinson, Franklin Lakes, NJ, USA) for measurement of CRP and PCT.
162 The specimens were allowed to clot for 30 minutes and centrifuged for 10 minutes at 2000xg
163 and the serum was subjected for analysis. The assays were performed within 2 hours of
164 specimen collection.

165 CRP was measured by immunturbidimetric method (3. generation C-reactive protein kit,
166 Roche, Mannheim, Germany) on Roche Cobas c501 analyzer (Roche, Mannheim, Germany).
167 The detection limit was <0.3 mg/L and the measuring range was 0.3–350 mg/L. The interassay
168 CVs at 2.36 and 157 mg/L concentrations were 1.3% and 11%, respectively.

169 PCT was measured by electrochemiluminescence immunoassay method (Elecsys BRAHMS
170 PCT kit, Roche, Mannheim, Germany) on an automated Cobas e601 analyzer (Roche,
171 Mannheim, Germany). The detection limit was ≤ 0.02 $\mu\text{g/L}$ and the measuring range was 0.02-
172 100 $\mu\text{g/L}$. The interassay CVs at 0.431 $\mu\text{g/L}$ and 54.4 $\mu\text{g/L}$ were 2.6% and 1.6%, respectively.

173 *Statistical analysis*

174 Distribution of data was analyzed with standard Kolmogorov-Smirnov (K-S) test. Interestingly,
175 blood pressure showed normal distribution, while all other descriptive parameters were not
176 normally distributed. Descriptive statistics were made with means and standard deviations or
177 medians and interquartile ranges (25 and 75 %), respectively. Analysis of differences between
178 groups were calculated using one-way ANOVA (Levene' F) or Kruskal – Wallis test with post

179 hoc Bonferroni correction, based on the distribution of the data. Any difference was considered
 180 significant above $p=0.05$ level, and confidence intervals were set to 95%.

181 Performance of cell population data (CPD) parameters were investigated with ROC (Receiver
 182 Operating Curve) analysis. Cutoff values were set using Youden's method, based on AUC (area
 183 under the curve) analysis. Data performance was considered good above 0.8, and excellent
 184 above 0.9 AUC, respectively.

185 **Results**

186 From September 2019 to January 2020 overall 452 patients were enrolled to the study, who
 187 arrived at the emergency department with a suspected infection. Data were collected from the
 188 electronic patient records. After clearing the raw data, in 176 cases SOFA score was incomplete,
 189 therefore these cases were excluded from the study.

190 The baseline and descriptive characteristics of the whole cohort are summarized in Table 2 and
 191 3.

Baseline demographics	no infection (N=86)	infection (N=37)	sepsis (N=129)	septic shock (N=24)
Age (years)	63 (50.7-80)	67 (56.5-76)	74 (66.5-84)	80.5(72.2-84.7)
Females	35 (40.7%)	18 (48.6%)	72 (55.8%)	7 (29.2%)
Source of infection	n/a			
<i>lower respiratory tract</i>	<i>n/a</i>	<i>14 (37.8%)</i>	<i>54 (41.9%)</i>	<i>6 (25 %)</i>
<i>upper respiratory tract</i>	<i>n/a</i>	<i>2 (5.4%)</i>	<i>3 (2.3%)</i>	<i>2 (8.3%)</i>
<i>gastrointestinal</i>	<i>n/a</i>	<i>2 (5.4%)</i>	<i>4 (3.1%)</i>	<i>0 (0%)</i>
<i>intraabdominal</i>	<i>n/a</i>	<i>3 (8.1%)</i>	<i>17 (13.2%)</i>	<i>2 (8.3%)</i>
<i>Skin/soft tissue</i>	<i>n/a</i>	<i>5 (13.5%)</i>	<i>10 (7.8%)</i>	<i>1 (4.2%)</i>

<i>central nervous system</i>	<i>n/a</i>	1 (2.7%)	1 (0.8%)	0 (0%)
<i>urinary tract</i>	<i>n/a</i>	8 (21.6%)	30 (23.3%)	10 (41.7%)
<i>bone</i>	<i>n/a</i>	0 (0%)	2 (1.6%)	0 (0%)
<i>unknown</i>	<i>n/a</i>	2 (5.4%)	8 (6.2%)	3 (12.5%)

192 *Data are summarized as median (with quartiles 25%-75%) or frequency (percentage) as appropriate*

193 Table 2. Baseline characteristics of the whole sample (N=276)

Variables	no infection (N=86)	infection (N=37)	sepsis (N=129)	septic shock (N=24)	significance*
systolic RR	141.66 (26.82)	134.49 (19.12)	121.67 (30.13)	96.63 (29.62)	p=0.000
diastolic RR	82.29 (17.46)	78.35 (13.78)	67.43 (18.26)	52.92 (19.75)	p=0.000
mean arterial pressure (MAP)	102.08 (18.98)	97.06 (14.45)	85.51 (20.77)	67.48 (22.14)	p=0.000
Respiratory rate (RR)	17 (16-20)	19 (17-22)	20 (17-24)	24 (18-36)	p=0.000
Glasgow Coma Scale (GCS)	15 (15)	15 (15)	15 (14-15)	10 (5-14)	p=0.000-0.012
SOFA	1 (0-3)	1 (1)	3 (2-4)	8 (7-10)	p=0.000-0.033
Microbiology positivity rate	1/86 (1.1%)	15/37 (40.54 %)	76/129 (58.9 %)	19/24 (79.2%)	p=0.000-0.002

194 *Data are summarized as mean (standard deviation), median (quartiles 25%-75%) or frequency (percentage) as*
195 *appropriate*

196 Table 3. Descriptive parameters of the whole sample (N=276)

197 In 66 cases, microbiology results were not available at the time of the data collection, and the
198 confirmation of the initial diagnosis was based on imaging results. These cases were excluded
199 from the final sample, and data of the remaining 210 patients were analyzed separately (Table
200 3 and 4).

201 In the “No infection” group (N=82) although the initial impression was suspected infection,
 202 non-infective underlying conditions were proven, and infection was ruled out. In patients with
 203 proven infection SOFA score was calculated and need for noradrenalin and lactate elevation
 204 were taken into consideration in forming the other three groups: “Infection”: SOFA<2 (N=16),
 205 “Sepsis”: SOFA \geq 2 (N=89) and ”Septic shock”: SOFA \geq 2 + need for noradrenalin and lactate
 206 level > 2mmol/L (N=23).

207 Baseline and descriptive characteristics of the final sample can be seen in Table 4 and 5.

Baseline demographics	no infection (N=82)	infection (N=16)	sepsis (N=89)	septic shock (N=23)
Age (years)	63 (49-79.2)	65 (55.7-78)	74 (68-84)	81 (73-85)
Females	33 (40.2%)	9 (56.3%)	50 (56.2%)	7 (30.4%)
Source of infection	n/a			
<i>lower respiratory tract</i>	<i>n/a</i>	3 (18.8%)	36 (40.4%)	5 (21.7%)
<i>upper respiratory tract</i>	<i>n/a</i>	0 (0%)	0 (0%)	2 (8.7%)
<i>gastrointestinal</i>	<i>n/a</i>	2 (12.5%)	3 (3.4%)	0 (0%)
<i>intraabdominal</i>	<i>n/a</i>	0 (0%)	10 (11.2%)	2 (8.7%)
<i>Skin/soft tissue</i>	<i>n/a</i>	1 (6.3%)	6 (6.7%)	1 (4.3%)
<i>central nervous system</i>	<i>n/a</i>	1 (6.3%)	0 (0%)	0 (0%)
<i>urinary tract</i>	<i>n/a</i>	8 (50%)	26 (29.2%)	10 (43.5%)
<i>bone</i>	<i>n/a</i>	0 (0%)	2 (2.2%)	0 (0%)
<i>unknown</i>	<i>n/a</i>	1 (6.3%)	6 (6.7%)	3 (13%)

208 *Data are summarized as mean (min-max) or frequency (percentage) as appropriate*

209 Table 4. Baseline characteristics of the final sample (N=210)

210

Variables	no infection (N=82)	infection (N=16)	sepsis (N=89)	septic shock (N=23)	significance*
systolic RR	142.5* (26.54)	129.6* (17.49)	118.5 (30.7)	93.78* (26.7)	p=0.000* 1.000
diastolic RR	82.93* (17.1)	78.56* (11.8)	65.04 (17.84)	51.04* (17.9)	p=0.000* 1.000
mean arterial pressure (MAP)	102.7* (18.54)	95.58* (12.94)	82.88 (20.65)	65.29* (19.78)	p=0.000* 1.000
Respiratory rate (RR)	17* (16-20)	18 (17-21)	20 (18-25)	24* (18-35)	p=0.000* 1.000
Glasgow Coma Scale (GCS)	15 (15)	15 (15)	15 (14-15)	10* (5-15)	p=0.000* 1.000
SOFA	1 (0-2)	1 (1)	4 (3-5)	8* (7-10)	p=0.000* 0.898
Microbiology positivity rate	0/82 (0%)	16/16 (100 %)	89/89 (100 %)	23/23 (100%)	p<0.001

211 *: One-way ANOVA (Levene' F) or Kruskal – Wallis test with post hoc Bonferroni correction, based on the
212 distribution of the data

213 Table 5. Descriptive parameters of the final sample (N=210)

214 All statistical tests were performed in both samples (ie. the whole cohort and final sample), and
215 interestingly, the same pattern can be seen in almost every examined variable (Table 3 and 5.)

216 Although this was not among the main reasons behind our study, in our interpretation, this
217 finding confirms the validity of the clinical decision in cases when no microbiology results are
218 available.

219 *CRP, PCT and WBC performance*

220 Standard infection markers were also compared in all groups. White blood cell count (WBC)
221 and C-reactive Protein (CRP) was significantly lower in non-infected than in every other group

222 (10.55 vs 81.35-131.3, $p < 0.001$). These parameters showed no statistical difference between
 223 the other three groups of infection, sepsis and septic shock. Procalcitonin (PCT) showed
 224 significant difference between almost all groups, respectively (0.068 – 4.73, $p = 0.000-0.024$);
 225 no significant difference could be measured between infection and sepsis group (0.16 vs 0.756,
 226 $p = 0.074$) (Table 6.).

Parameters	no infection (N=82)	infection (N=16)	sepsis (N=89)	septic shock (N=23)	significance
CRP	10.55* (3.52- 27.82)	81.35 (34.8- 173.6)	118.25 (55.7- 212.3)	131.3 (82 - 223.7)	$p < 0.001^*-1.000$
PCT	0.068 (0.05- 0.126)	0.16 (0.091-0.5)	0.756 (0.28-5.03)	4.73* (0.54 - 20.92)	$p = 0.000^*-0.965$
WBC	9.49* (8.12- 11.25)	15.03 (9.1- 17.24)	11.95 (9.24- 17.96)	13.58 (9.03- 20.48)	$p = 0.000^*-1.000$

227 Table 6. Standard biomarkers in Sepsis-3 cohorts

228 *Performance of CPD parameters*

229 As a second step cell population data were analyzed. Ne-SSC, NeFSC/M, MoZ/M and Mo-
 230 WZ/M showed normal distribution, all the other parameters were not normally distributed.
 231 According to the descriptive analysis multiple parameters showed significant changes. The
 232 highlighted NE-SFL/M, MO-X/M and NE-WY/M parameters showed significant changes
 233 between septic shock and the other groups (Table 7.)


Parameters	no infection (N=82)	infection (N=16)	sepsis (N=89)	septic shock (N=23)	significance
NEUT #	6.595* (5.29- 8.51)	11.94 (7.38- 15.23)	9.92 (7.27 - 14.07)	12.79 (8.51 - 21.01)	$p = 0.000^*-1.000$
NEUT %	73.25* (62.55- 79.65)	86.15 (77.55 - 89.2)	86.8 (79.55 - 91.45)	87.2 (83 - 94.4)	$p = 0.000^*-1.000$

IGR	0.4 (0.3-0.6)	0.65 (0.4 – 1.05)	0.7 (0.5 – 1.35)	1* (0.4 – 3.4)	p=0.000*-1.000
NE-SSC	149.59 (4.45)	152.91 (3.86)	150.49 (5.12)	150.2 (4.18)	p=0.068
NE-SFL/M	39.5 (37.9-41.2)	40.6 (39.6 – 41.52)	43.8 (41.5 – 47.5)	46.6* (42.5 – 54.2)	p=0.000*-1.000
NE-FSC/M	81.6 (3.78)	82.03 (3.35)	80.04 (4.66)	80.9 (4.4)	p=0.053
LY-X/M	78.9 (77.7-80.6)	78.45 (76.85 – 80.4)	79.6 (77.9 – 81.1)	81.7* (78.8 – 83.1)	p=0.005*-1.000
LY-Y/M	61.4 (58.6-63.3)	57.95 (55.5 – 60.72)	59.7 (56.25 – 63.8)	61.6 (56.8 – 65.8)	p=0.052-1.000
LY-Z/M	55.9 (55-56.4)	55.5 (54.7-56.3)	55.6 (54.3 – 56.75)	56.6 (54.8 – 58.7)	p=0.062
MO-X/M	117.4* (115.9-118.8)	120.1 (119.17 – 121.22)	120.8 (118.5 – 122.8)	123.1 (120.8 – 127.9)	p=0.000*-1.000
MO-Y/M	92.6* (88.3-96.2)	95.45 (93.95 – 102.6)	96.2 (91.05-103.3)	100.1 (95.1 – 107.9)	p=0.000*-1.000
MO-Z/M	61.54 (2.4)	61.36 (2.62)	61.38 (3.03)	63.05 (2.72)	p=0.097
NE-WX/M	320 (310.5-330)	322.5 (305 – 333)	323 (313.5 – 334)	330 (315 – 338)	p=0.205
NE-WY/M	658 (626-688.5)	678 (658.75 – 736)	726 (678 – 796)	831* (753 – 945)	p=0.000*-0.364
NE-WZ/M	712 (691.5-746)	712.5 (683.5 – 753.7)	723 (699 – 747.5)	747 (698 – 774)	p=0.129
LY-WX/M	469* (444.5-504.5)	505.1 (437.25 – 551)	508 (450.5 – 546.5)	500 (447 – 531)	p=0.013*-1.000
LY-WY/M	874 (836-916)	883 (804.5 – 1101.2)	941* (840.5 – 1068.5)	931 (842 – 1084)	p=0.009*-1.000
LY-WZ/M	577 (556.5-588.5)	568 (564 – 609.7)	586 (561 – 629.5)	592 (524 – 645)	p=0.140
MO-WX/M	261 (249-276)	252 (242 – 267.5)	272 (250.5 – 290)	266 (257 – 296)	p=0.055-1.000

MO-WY/M	715 (678.5-759.5)	759.5 (677.5 – 836.5)	748 (682 – 825.5)	754 (714 – 818)	p=0.08
MO-WZ/M	671.77 (67.37)	661.1 (48.76)	667.79 (84.4)	689.83 (72.24)	p=0.769

234 Table 7. Performance of CPD parameters in Sepsis-3 cohorts


235 As a third step, ROC analyses aiming to validate the performance of all CPD parameters were
 236 carried out in each subgroup. As seen in Figures 1-4, NE-SFL/M, MO-X/M and NE-WY/M
 237 emerged from the dataset with clinical progression of the inflammatory response. These
 238 parameters showed no notable performance in earlier stages, but in septic shock, AUC's became
 239 significantly remarkable (NE-SFL/M=0.745; MO-X/M=0,77; NE-WY/M=0.826; all p<0.001).



240

241 Figure 1. ROC analysis of no infection group


242



243


244 Figure 2. ROC analysis of infection group

245



246

247 Figure 3. ROC analysis of sepsis group



248

249 Figure 4. ROC analysis of septic shock group

250

251 *Cell population data markers in septic shock*

252 Using Youden's method to determine the best cutoff values, NE-SFL/M, MO-X/M and NE-

253 WY/M emerged from CPD dataset. These group of variables were set as a new index, Ne₂Mo.

254 Sensitivity and specificity measurements showed acceptable performance. (Table 8.)

	suggested cutoff value	sensitivity	specificity
NE-SFL/M	44.45	0.696	0.780
MO-X/M	120.75	0.826	0.710
NE WY/M	751.5	0.783	0.770

255 Table 8. Ne₂Mo suggested cutoff performances


256 Using the above cutoff values, ROC analysis was carried out using positive Ne₂Mo against

257 septic shock as a grouping variable. ROC analysis showed AUC of 0.828, which means good

258 but not excellent diagnostic accuracy for septic shock. (data not shown)

259 *Quick SOFA and CPD combined performance as an early marker of septic shock*

260 Since Ne₂Mo score is completely based on the laboratory results, an idea of incorporating the
261 clinical presentation emerged. Quick SOFA (qSOFA) is a widely used scoring system for
262 identifying high-risk patients for in-hospital mortality with suspected infection outside the ICU
263 [14]. A new ordinal variable (qS-Ne₂Mo) was formed by forging qSOFA and Ne₂Mo. qS-
264 Ne₂Mo is a 6-point scale, scoring 1 point each for the positive qSOFA items or Ne₂Mo values
265 above the suggested cutoffs. As seen in Figure 5, this new score enhances the individual
266 performance of the single items, with remarkable diagnostic ability for septic shock (AUC of
267 0.914, p<0.001). Setting the cutoff for 4 points for this score results in good sensitivity (73.9%)
268 and excellent specificity (89 %).



269
270 Figure 5. ROC analysis of qS-Ne₂Mo score in septic shock

271
272 After setting the cutoff to 4 points in qSNe₂Mo, risk estimates were calculated for each group
273 of patients. Odds ratio (OR) for infection was 0.839; sepsis 1.681 and septic shock 22.56.

274 According to this estimation, having 4 or more points in the score is signaling elevated risk of
275 either being septic or in septic shock.

276 **Discussion**

277 In this retrospective study we aimed to assess the possible application of CPD parameters in
278 sepsis recognition comparing them to regular infection markers. Also, we aimed to find the
279 possible role of CPD parameters when combined with the initial recommended screening tool,
280 qSOFA.

281 Recently several articles were published about possible use of CPD parameters measured by
282 Sysmex XN analyzers in sepsis management. In Park's study NE-SFL and NE-WY (two CPD
283 parameters represent neutrophil immaturity or activation) were found useful in detection of
284 sepsis, but no strong correlation with severity was found [10]. In pediatric population, Biban
285 and his team found significantly higher values of NE-SFL, MO-WX, and MO-Y CPD
286 parameters among children with sepsis or septic shock on admission to intensive care unit [2].
287 Urrechaga and her team suggested the use of NEMO score as a risk stratification scale in sepsis
288 using two CPD parameters: MO-X and NE-SFL [17]. Urrechaga in a following article found
289 that among septic cases those CPD parameters were higher which represented the monocyte
290 complexity and the neutrophil leucocyte activation (NE-SFL, NE-WY, MO-X, MO-WX and
291 MO-Z) [18]. Buoro and her team reached similar conclusions that MO-X and NE-SFL showed
292 the best performance in detecting sepsis, though almost all the parameters were significantly
293 higher in patients admitted to ICU compared to healthy subjects [3].

294 Our results suggested that although almost all CPD parameters showed significant changes in
295 the different groups, but no single parameter showed a convincing correlation with the final
296 sepsis diagnosis (SOFA \geq 2). In comparison with the regular parameters no superior CPD value
297 was identified.

298 From our initial results, where CPD parameters were compared in each study groups, three
299 parameters (NE-SFL/M, MO-X/M and Ne-WY/M) showed significant results in distinguishing
300 septic shock from sepsis, infection and no infection and we also achieved good results with
301 ROC analysis comparing these parameters with the diagnosis of septic shock. Determining the
302 cutoff values for these parameters and combining them with the qSOFA score we formed a six-
303 point scale – qS-Ne2Mo – which can predict the presence of septic shock with a cutoff value
304 of 4 points.

305 To complete qS-Ne2Mo score, simple vital signs and no additional blood samples are needed.
306 With the fast turn-around-time of CPD, qS-Ne2Mo score can be completed within a short period
307 of time starting from triage and can identify septic shock patients way before the completion of
308 SOFA score or before the initial resuscitation attempts would have results.

309 *Possible fields of application of qS-Ne2Mo score*

310 Final septic shock diagnosis can be made only after the initial treatment attempt, and only the
311 therapy refractory cases need vasopressors and have constantly high lactate levels. During the
312 initial management of septic patients, it is unclear how vehement treatment approach is the right
313 choice. In 2001, Rivers et al. found that early goal directed therapy reduced the mortality in
314 severe sepsis and septic shock, and this type of treatment came with higher fluid doses more
315 transfusions and with earlier dobutamine treatment. In the Rivers study the initial marker of
316 severe sepsis and septic shock was at least two of possible four SIRS criteria with systolic blood
317 pressure no higher than 90 mmHg after initial fluid challenge (20-30mL/bodyweight infusion
318 under 30 minutes) or a serum lactate level 4mmol/L or more [13]. The current 2016 SSC
319 guidelines do not recommend against the early goal-directed therapy (EGDT) but advise a more
320 relaxed approach in fluid challenge 30mL/kg over three hours, and a sort of a wait-and-see
321 approach is promoted to decide how the patient's hemodynamic status changes during this 3-
322 hour period. Although EGDT showed breakthrough results in reduction of severe sepsis and

323 septic shock related mortality compared to standard therapy, now this approach has been
324 challenged by many recent randomized controlled trials, that failed to reproduce those excellent
325 results in the Rivers study [1, 9, 12]. Maybe, this controversy lies in the fact that only the most
326 severe cases can profit from EGDT (i.e. septic shock), but on arrival no certain marker
327 distinguishes those patients and the initial indicators for early septic shock were insufficient.
328 With qS-Ne2Mo score, septic shock can be identified early and reliably and maybe more
329 aggressive treatment strategy like EGDT can be justified by positive qS-Ne2Mo score.

330 In the current updated Surviving Sepsis Campaign (SSC) guidelines a 1-hour time-window is
331 recommended to complete lactate measurement, start fluid resuscitation, obtain blood cultures,
332 and commence broad-spectrum antibiotics in suspected sepsis or septic shock cases [7]. This
333 early antibiotic therapy is highly debated. Many articles question the advantages of a rushed
334 antibiotic administration in all septic cases, but it is generally accepted that in septic shock one
335 of the cornerstones of the successful therapy is the prompt initiation of antibiotics [6, 15]. With
336 qS-Ne2Mo score septic shock can be identified very early. qS-Ne2Mo may be a good clinical
337 tool for selecting patients who are eligible for immediate (within 1 hour) broad spectrum
338 antibiotic treatment, while others can wait for more thorough investigations, and can receive a
339 more targeted antibiotic treatment which might lower the current extreme rise of antibiotic
340 resistant strains.

341 Finally, we must mention the possible economic role of using CPD parameters and the qS-
342 Ne2MO score. CPD comes with an additional 50% price on top of a regular CBC measurement,
343 still not reaching the price of a single CRP measurement not to mention PCT which costs
344 approximately 20 times more than a CBC and CPD measurement together. Therefore qS-
345 Ne2Mo score might be used as an initial screening tool to select only those patients that need
346 more extensive laboratory investigations for their proper treatment and spare inadequate, time
347 and money consuming laboratory requests. In places where CBC is used solely with CRP and

348 PCT is not available, CPD parameters and qS-Ne2Mo score could be a very useful tool to
349 enhance performance of sepsis management.

350 *Limitations*

351 Our study has certain limitations. The sample size was relatively small to come to firm
352 conclusions. Furthermore, we cannot make any comments on the efficacy and outcomes of a
353 qS-Ne2Mo based approach in the management of this patient population.

354 **Conclusion**

355 In this retrospective observational study, we examined the possible role of CPD parameters in
356 sepsis and septic shock diagnosis. According to our results combining the qSOFA score with
357 three CPD parameters, a new risk stratification score was developed to identify septic shock
358 early. qS-Ne2MO score showed promising prognostic value for the final diagnosis of septic
359 shock using the current Sepsis-3 criteria. For the suggested applications of qS-Ne2Mo score,
360 further studies are required to provide the sufficient evidence for safe clinical use.

361 **Declarations**

362

363 *Ethics approval and consent to participate*

364 This study was approved by the University of Szeged Ethical Committee (ref nr. 25/2016-
365 SZTE).

366 *Consent for publication*

367 Not applicable.

368 *Availability of data and materials*

369 Research data is available upon reasonable request to the corresponding author.

370 *Competing interests*

371 The authors declare that they have no known competing financial interests or personal
372 relationships that could have appeared to influence the work reported in this paper.

373 *Funding*

374 The authors received no funding regarding this study.

375 *Authors' contributions*

376 PE: participated in design of the study and in patient selection, drafted the manuscript

377 LP: created data-analysis framework, provided the data analysis, wrote the original and revised
378 draft

379 IF: created the original idea and conceptualization, provided laboratory data, wrote original and
380 revised draft

381 KF: carried out hematology analysis, provided laboratory data and consultancy

382 ZM: supervised the manuscript, participated in data analysis

383 ZP: created the original idea and conceptualization, supervised the draft writing process

384 All authors read and approved the final manuscript

385

386 *Acknowledgement*

387 The authors are grateful to Ms. Anita Ildikó Kiss for her excellent technical assistance in
388 measurements and data collection of hematological tests.

389

390 **List of abbreviations**

391

392 ABG: additional painful blood works

393 AUC: area under the curve
394 CBC: complete blood count
395 CPD: cell population data
396 CRP: c-reactive protein
397 EGDT: early goal-directed therapy
398 GCS: Glasgow coma scale
399 MAP: mean arterial pressure
400 PCT: procalcitonin
401 qSOFA: quick Sequential Organ Failure Assessment
402 qS-Ne2Mo: quick SOFA combined with NE-SFL/M, MO-X/M and NE-WY/M
403 ROC analysis: receiver operating curve analysis
404 SIRS: systemic inflammatory response syndrome
405 SOFA: Sequential Organ Failure Assessment
406 SSC: surviving sepsis campaign
407 WBC: white blood cell

408

409 **References**

410

- 411 1. ARISE Investigators, ANZICS Clinical Trials Group, Peake, S. L., Delaney, A., Bailey,
412 M., Bellomo, R., Cameron, P. A., Cooper, D. J., Higgins, A. M., Holdgate, A., Howe,
413 B. D., Webb, S. A., & Williams, P. Goal-directed resuscitation for patients with early
414 septic shock. *N Engl J Med* 2014; 371:1496-1506. DOI: 10.1056/NEJMoa1404380
- 415 2. Biban P, Teggi M, Gaffuri M, Santuz P, Onorato D, Carpenè G, Gregori D and Lippi
416 G. Cell Population Data (CPD) for Early Recognition of Sepsis and Septic Shock in
417 Children: A Pilot Study. *Front. Pediatr.* 2021; 9:642377. doi:
418 10.3389/fped.2021.642377

- 419 3. Buoro S, Seghezzi M, Vavassori M, Dominoni P, Apassiti Esposito S, Manenti B,
420 Mecca T, Marchesi G, Castellucci E, Azzarà G, Ottomano C, Lippi G. Clinical
421 significance of cell population data (CPD) on Sysmex XN-9000 in septic patients with
422 our without liver impairment. *Ann Transl Med* 2016; 4(21):418. doi:
423 10.21037/atm.2016.10.73
- 424 4. Centers for Disease Control and Prevention. Sepsis. Clinical Information. (online) Page
425 last reviewed. December 7, 2020. Accessed April 14, 2021.
- 426 5. Karon BS, Tolan NV, Wockenfus AM, Block, DR, Baumann NA, Bryant SC, Clements
427 CM. Evaluation of lactate, white blood cell count, neutrophil count, procalcitonin and
428 immature granulocyte count as biomarkers for sepsis in emergency department patients.
429 *Clin Biochem.* 2017; 50(16-17):956-958. doi:10.1016/j.clinbiochem.2017.05.014
- 430 6. Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R.,
431 Feinstein, D., Zanotti, S., Taiberg, L., Gurka, D., Kumar, A., & Cheang, M. Duration of
432 hypotension before initiation of effective antimicrobial therapy is the critical
433 determinant of survival in human septic shock. *Critical care medicine*, 2006;
434 34(6):1589–1596. <https://doi.org/10.1097/01.CCM.0000217961.75225.E9>
- 435 7. Levy, M. M., Evans, L. E., & Rhodes, A. The surviving sepsis campaign bundle: 2018
436 update. *Intensive Care Med* 2018 Jun;44(6):925-928. doi: 10.1007/s00134-018-5085-0.
- 437 8. Maitra S, Som A, Bhattacharjee S. Accuracy of quick Sequential Organ Failure
438 Assessment (qSOFA) score and systemic inflammatory response syndrome (SIRS)
439 criteria for predicting mortality in hospitalized patients with suspected infection: a meta-
440 analysis of observational studies. *Clin Microbiol Infect.* 2018; 24(11):1123-1129.
441 doi:10.1016/j.cmi.2018.03.032
- 442 9. Mouncey, P. R., Osborn, T. M., Power, G. S., Harrison, D. A., Sadique, M. Z., Grieve,
443 R. D., Jahan, R., Harvey, S. E., Bell, D., Bion, J. F., Coats, T. J., Singer, M., Young, J.
444 D., Rowan, K. M., & ProMISe Trial Investigators. Trial of early, goal-directed
445 resuscitation for septic shock. *N Engl J Med* 2015; 372:1301-1311 DOI:
446 10.1056/NEJMoa1500896
- 447 10. Park, S.H., Park, C.-J., Lee, B.-R., Nam, K.-S., Kim, M.-J., Han, M.-Y., Kim, Y.J., Cho,
448 Y.-U. and Jang, S. Sepsis affects most routine and cell population data (CPD) obtained
449 using the Sysmex XN-2000 blood cell analyzer: neutrophil-related CPD NE-SFL and
450 NE-WY provide useful information for detecting sepsis. *Int. Jnl. Lab. Hem.*, 2015; 37:
451 190-198. <https://doi.org/10.1111/ijlh.12261>

- 452 11. Perman, S.M., Mikkelsen, M.E., Goyal, M., Ginde, A., Bhardwaj, A., Drumheller, B.,
453 Cham Sante, S., Agarwal A.K., Gaieski, D.F. The sensitivity of qSOFA calculated at
454 triage and during emergency department treatment to rapidly identify sepsis patients.
455 Sci Rep 2020; 10:20395 <https://doi.org/10.1038/s41598-020-77438-8>
- 456 12. ProCESS Investigators, Yealy, D. M., Kellum, J. A., Huang, D. T., Barnato, A. E.,
457 Weissfeld, L. A., Pike, F., Terndrup, T., Wang, H. E., Hou, P. C., LoVecchio, F., Filbin,
458 M. R., Shapiro, N. I., & Angus, D. C. A randomized trial of protocol-based care for
459 early septic shock. N Engl J Med 2014; 370:1683-1693 DOI: 10.1056/NEJMoa1401602
- 460 13. Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E.,
461 Tomlanovich, M., & Early Goal-Directed Therapy Collaborative Group. Early goal-
462 directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;
463 345:1368-1377 DOI: 10.1056/NEJMoa010307
- 464 14. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD Scherag A, Rubenfeld
465 G, Kahn JM, Shankar-Hari M, Singer M, Deutschman CS, Escobar GJ, Angus DC.
466 Assessment of Clinical Criteria for Sepsis For the Third International Consensus
467 Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762-774.
468 doi:10.1001/jama.2016.0288.
- 469 15. Sherwin, R., Winters, M. E., Vilke, G. M., & Wardi, G. Does Early and Appropriate
470 Antibiotic Administration Improve Mortality in Emergency Department Patients with
471 Severe Sepsis or Septic Shock? The Journal of Emergency Medicine, 2017; 53(4), 588–
472 595. <https://doi.org/10.1016/j.jemermed.2016.12.009>
- 473 16. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
474 Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801–810.
475 doi:10.1001/jama.2016.0287
- 476 17. Urrechaga, E., Bóveda, O., & Aguirre, U. Role of leucocytes cell population data in the
477 early detection of sepsis. Journal of Clinical Pathology, 2018; 71(3), 259–266.
478 <https://doi.org/10.1136/jclinpath-2017-204524>
- 479 18. Urrechaga E, Bóveda O, Aguirre U. Improvement in detecting sepsis using leukocyte
480 cell population data (CPD). Clin Chem Lab Med. 2019; 57(6):918-926. doi:
481 10.1515/cclm-2018-0979. PMID: 30838839.
- 482